ReviewFrontiers in cellular and infection microbiology2014
The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.
Review in Frontiers in cellular and infection microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Mucosomes as next-generation drug carriers for treating mucus-resident bacterial infections and biofilms.Scientific reports · 2025Article
- Preparation of RGD-modified liposomes encapsulated with shikonin and its targeted anti-melanoma effects.Frontiers in oncology · 2025Article
- Tularemia treatment: experimental and clinical data.Frontiers in microbiology · 2023Review
- Recent applications and strategies in nanotechnology for lung diseases.Nano research · 2021Review
- Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones.Pharmaceutics · 2020Review
- Article
- Properties and applications of nanoparticle/microparticle conveyors with adjuvant characteristics suitable for oral vaccination.International journal of nanomedicine · 2018Review
- Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis.Antimicrobial agents and chemotherapy · 2017Article
- Lysozyme Associated Liposomal Gentamicin Inhibits Bacterial Biofilm.International journal of molecular sciences · 2017Article
- Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.Frontiers in microbiology · 2017Article
- Development of Liposomal Ciprofloxacin to Treat Lung Infections.Pharmaceutics · 2016Review
- Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.Drug design, development and therapy · 2016Article
- pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.Small (Weinheim an der Bergstrasse, Germany) · 2015Article
- Distribution and Inhibition of Liposomes on Staphylococcus aureus and Pseudomonas aeruginosa Biofilm.PloS one · 2015Article
- Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.Current pharmaceutical design · 2015Review
- New anti-infective strategies for treatment of tularemia.Frontiers in cellular and infection microbiology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposome-encapsulation has been suggested as method to improve the efficacy of ciprofloxacin against the intracellular pathogen, Francisella tularensis. Early work with a prototype formulation, evaluated for use against the F. tularensis live vaccine strain, showed that a single dose of liposomal ciprofloxacin given by the intranasal or inhalational route could provide protection in a mouse model of pneumonic tularemia. Liposomal ciprofloxacin offered better protection than ciprofloxacin given by the same routes. Liposomal ciprofloxacin has been further developed by Aradigm Corporation for Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. This advanced development formulation is safe, effective and well tolerated in human clinical trials. Further evaluation of the advanced liposomal ciprofloxacin formulation against the highly virulent F. tularensis Schu S4 strain has shown that aerosolized CFI (Ciprofloxacin encapsulated in liposomes for inhalation) provides significantly better protection than oral ciprofloxacin. Thus, liposomal ciprofloxacin is a promising treatment for tularemia and further research with the aim of enabling licensure under the animal rule is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.